AgeX Therapeutics Inc
Research AgeX Therapeutics Inc (SER) on Bullrun: market cap USD 68.58M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSER
- ExchangeNYSE MKT
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 68.58M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 6.90M
- Free cash flow-USD 4.59M
Valuation Snapshot
latest market cap is USD 68.58M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 130.00K | -USD 19.18M | -USD 18.01M | n/a | -1.91 | USD 3.06M | USD 3.14M | -USD 37.00K |
| FY2024 | USD 56.00K | -USD 11.14M | -USD 17.16M | n/a | -1.51 | USD 3.67M | USD 268.00K | USD 641.00K |
| FY2023 | USD 3.15M | USD 5.27M | -USD 2.98M | 3.2% | 0.73 | USD 7.62M | USD 3.45M | -USD 32.29M |
| FY2022 | USD 34.00K | -USD 10.46M | n/a | 61.8% | -9.7 | USD 645.00K | USD 18.12M | -USD 37.78M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 68.58M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 20.56M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 47.20M | n/a | n/a | n/a |
About AgeX Therapeutics Inc
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is AgeX Therapeutics Inc's market cap?
AgeX Therapeutics Inc's market capitalization is USD 68.58M.
What does AgeX Therapeutics Inc do?
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial.